WEDNESDAY, Dec. 21 (HealthDay News) -- Jack Whelan first knew  something was wrong when it got harder and harder to walk from the train  station in Boston to the financial district where he worked. 
                 He knew something was terribly wrong when he started getting nose  bleeds. 
                 A consultation with an oncologist confirmed Whelan's fears: He had  advanced Waldenstrom's macroglobulinemia, a rare form of blood cancer that  affects only about 1,500 people in the United States each year. 
                 Forty years ago, Whelan would have had five years to live -- at the  outside -- and who knows what his quality of life would have looked  like.
                 But today, five years after his diagnosis and almost 40 years to the  day that President Richard Nixon signed the National Cancer Act declaring  "war" on cancer, Whelan, 63, is power-walking, raking leaves, shoveling  snow and back at work as a marketing executive. 
                 Whelan is just one of the millions of Americans who have benefited from  continued advances in cancer research.  He has participated in four  different clinical trials and is currently taking an experimental drug  called LBH589 which, Whelan said, makes him "feel like Popeye the sailor  after having spinach."
                 Just this month, scientists at the Dana-Farber Cancer Institute in  Boston, where Whelan is being treated, discovered a single gene mutation  present in 90 percent of patients who have this rare type of cancer,  raising the hope that an even more targeted treatment will soon be able to  attack the disease.
                 Since Dec. 23, 1971, and the passage in Congress of the National Cancer  Act, research has made tremendous progress against what is still one of  the world's foremost killers, experts say. 
                 "Back at that time point, cancer essentially was a death sentence,"  said Dr. Raymond N. DuBois Jr., provost and executive vice president for  academic affairs at M.D. Anderson Cancer Center in Houston.
                 That's no longer the case, however, thanks to advances in early  detection, improved therapies and a better understanding of the genetics  driving different forms of cancer, he said. 
                 "Forty years ago, fewer than one-third of patients with a diagnosis of  cancer lived five years. Almost no children with a diagnosis of the most  common form of childhood cancer, acute leukemia, lived [that long]," said  Dana-Farber president Dr. Edward Benz Jr. "In 2011, nearly 90 percent of  children diagnosed with acute leukemia will be cured and nearly two-thirds  of all people diagnosed with cancer will live at least five years."
                 Since 1991 alone, there's been more than an 18 percent reduction in  deaths from cancer, added Dr. Otis Brawley, chief medical officer of the  American Cancer Society. 
                 An ounce of prevention
                 Much of this progress may have started with prevention.  
                 Declines in smoking rates, helped by the landmark U.S. Surgeon  General's Report in 1964 linking smoking to cancer, have continued over  the decades, preventing countless cases of lung malignancies and other  forms of cancer. 
                 Colonoscopies to detect pre-cancerous polyps have not only reduced  mortality but prevented many cases of colorectal cancer outright. 
                 The adoption of regular mammography screening for breast cancer is  another success story in its own right, as is screening for cervical  cancer.
                 Thanks to, first, the Pap smear (which looks for abnormal cells on the  cervix) and now the HPV test (which detects the human papillomavirus that  can cause cervical cancer), death rates from cervical cancer in the United  States plummeted more than 60 percent between 1955 and 1992, according to  the U.S. National Cancer Institute.   
 No doubt, incidence and mortality from cervical cancer will continue to  decline with the advent of another major weapon: newly approved vaccines  that prevent infection with the strains of HPV that cause most cases of  this type of cancer.  
 These vaccines (two have been approved by the U.S. Food and Drug  Administration) have great potential to reduce head and neck cancers, as  well as anal cancer deaths, which can also be caused by HPV, Brawley said.   
 But advances in detection have been complemented by improvements in  treatment, the experts added. These include better surgical techniques.  For example, studies suggest that women who have a lumpectomy to conserve  their breast along with radiation typically have as good a prognosis as  women who undergo a full mastectomy. 
 Targeted radiation has also made treatment much less onerous for  prostate cancer patients, and new chemotherapies often arrive with  drastically fewer side effects than in decades past.  
 The age of "targeted therapies" or "personalized medicine" -- an era  ushered in by anti-estrogen breast cancer therapies such as tamoxifen  (which debuted in the 1980s) -- is here, Brawley said. Those highly  targeted medications were later joined by aromatase inhibitors as well as  Herceptin (trastuzumab) to attack a specific form of Her2neu-positive  breast cancer.  
 Scientists are also finding new targets for lung, colorectal and other  cancers. For example, studies show that Tarceva (erlotinib) can improve  the average survival of patients with non-small cell lung cancer by about  two months. That may not sound like much but, in lung cancer, it  represents a huge stride.  
 "Wonder drug" Gleevec, a medicine used to push certain blood cancers  into remission, is another targeted-therapy success story. In fact, a  colleague of Whelan's was diagnosed with chronic myelogenous leukemia  while still in his 20s and subsequently died. Had he been diagnosed a few  years later, after the discovery of Gleevec, he would have lived, Whelan  believes.  
 Brawley agrees that "personalized medicine is the future," and he  predicts many more advances in this area in the next five years.  
 Dubois added: "We are doing molecular fingerprinting of each individual  tumor and, although we're not using that right now to direct cancer care,  the idea is once we have that information we will be able to use it to  figure out exactly which treatments a patient needs so they're not being  given unnecessary treatment. And the treatment they do get is going to be  much more effective on the first round of therapy when it really makes the  biggest difference."  
 Doctors now also know that "multi-modality" therapy -- meaning the  combined use of surgery, radiation and drug therapy -- "has given people  the best chance for good outcomes for particular kinds of cancer," said  Benz.  
 Progress lacking on some fronts 
 But while there's been undisputed progress, "it's very incomplete  progress," Benz and others acknowledged.  
 "If you look over the past 40 years, on some fronts we've actually been  winning and on some fronts we're losing terribly," said Brawley. "We are  our own worst enemy in terms of battling cancer with tobacco control, diet  and exercise and getting everybody adequate preventive screening and  treatment. 
 "In excess of 200,000 of the 500,000 lives that will be lost from  cancer this year could have been avoided if we simply adopted all the  cancer-control technologies that we've learned over the last 40 years," he  added.  
 Although the smoking rate has declined dramatically since publication  of the U.S. Surgeon General's 1964 report, it's been stalled at about 20  percent for 10 years now, Brawley said.  
 There are also lingering disparities in both prevention and treatment  by race, socioeconomic status and urban versus rural locations, said  Brawley.  
 Cancer therapies are also becoming increasingly complicated and  expensive "at a time when the trend in health care and in support for  cancer research is going down," added Benz. "I worry that we're going to  see increasing disparities as cancer and personalized medicine becomes  more complicated and expensive. It will be harder and harder to offer it  to everybody who needs it." 
 Clinical trials may also become more difficult and expensive to  conduct, as scientists recognize more and more subtypes of cancer. That  means fewer people fit each particular subtype, Benz said.  
 Nevertheless, the overall message is a positive one. 
 "It's been a huge evolution since 1971," said DuBois. "It's just  incredible." 
 More information  
 There's more on the National Cancer Act at the U.S.  National Cancer Institute.
Source: http://us.rd.yahoo.com/dailynews/rss/cancer/*http%3A//news.yahoo.com/s/hsn/20111221/hl_hsn/40yearsonthetriumphsandchallengesofamericaswaroncancer
payroll tax payroll tax sugar cookie recipe sugar cookie recipe aisha khan alanis morissette standing rib roast